Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10,167 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.
Melichar B, Patenia R, Gallardo S, Melicharová K, Hu W, Freedman RS. Melichar B, et al. Among authors: hu w. Gynecol Oncol. 2007 Mar;104(3):707-13. doi: 10.1016/j.ygyno.2006.10.056. Epub 2006 Dec 12. Gynecol Oncol. 2007. PMID: 17166566
Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.
Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ. Hu W, et al. Int J Gynecol Cancer. 2002 Mar-Apr;12(2):202-7. doi: 10.1046/j.1525-1438.2002.01084.x. Int J Gynecol Cancer. 2002. PMID: 11975681
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.
Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD, Emons G. Verschraegen CF, et al. Among authors: hu w. Gynecol Oncol. 2003 Sep;90(3):552-9. doi: 10.1016/s0090-8258(03)00408-6. Gynecol Oncol. 2003. PMID: 13678723 Clinical Trial.
rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition.
Melichar B, Hu W, Patenia R, Melicharová K, Gallardo ST, Freedman R. Melichar B, et al. Among authors: hu w. J Transl Med. 2003 Sep 19;1(1):5. doi: 10.1186/1479-5876-1-5. J Transl Med. 2003. PMID: 14572312 Free PMC article.
Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression.
Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Melichar B, et al. Among authors: hu w. Gynecol Oncol. 2004 Apr;93(1):149-54. doi: 10.1016/j.ygyno.2004.01.008. Gynecol Oncol. 2004. PMID: 15047229
Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.
Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, Wang S, Zhou J, Hu W, Ma D. Yang X, et al. Among authors: hu w. J Cancer Res Clin Oncol. 2004 Jul;130(7):423-8. doi: 10.1007/s00432-004-0556-9. J Cancer Res Clin Oncol. 2004. PMID: 15156398
Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial.
Kim HG, Yamal JM, Xu XC, Hu W, Boiko I, Linares A, Vlastos AT, Atkinson EN, Malpica A, Hittelman WN, Follen M. Kim HG, et al. Among authors: hu w. Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S32-7. doi: 10.1016/j.ygyno.2005.07.039. Epub 2005 Sep 9. Gynecol Oncol. 2005. PMID: 16154183
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Li Y, et al. Among authors: hu w. Gynecol Oncol. 2007 Aug;106(2):375-80. doi: 10.1016/j.ygyno.2007.04.011. Epub 2007 May 18. Gynecol Oncol. 2007. PMID: 17512575
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.
Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Zheng H, et al. Among authors: hu w. Pharm Res. 2008 Oct;25(10):2272-82. doi: 10.1007/s11095-008-9621-4. Epub 2008 May 29. Pharm Res. 2008. PMID: 18509599
10,167 results
Jump to page